Premium
FDA authorizes marketing of diagnostic aid for Autism Spectrum Disorder
Author(s) -
Knopf Alison
Publication year - 2021
Publication title -
the brown university child and adolescent psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7567
pISSN - 1527-8395
DOI - 10.1002/cpu.30601
Subject(s) - autism spectrum disorder , food and drug administration , psychiatry , medicine , health care , autism , family medicine , psychology , business , medical education , marketing , medical emergency , economic growth , economics
In June, the U.S. Food and Drug Administration authorized marketing of a device to help diagnose autism spectrum disorder (ASD). The Cognoa ASD Diagnosis Aid is a machine learning‐based software intended to help health care providers diagnose ASD in children 18 months through 5 years of age who exhibit potential symptoms of the disorder.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom